Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Gout flares are driven by interleukin (IL)-1β. Dapansutrile inhibits the NLRP3 inflammasome and subsequent activation of IL-1β. In this study we aimed to investigate the safety and efficacy of orally administered dapansutrile in patients with a gout flare. In this open-label, proof-of-concept, phase...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet. Rheumatology 2020-05, Vol.2 (5), p.e270-e280
Hauptverfasser:	Klück, Viola, Jansen, Tim L Th A, Janssen, Matthijs, Comarniceanu, Antoaneta, Efdé, Monique, Tengesdal, Isak W, Schraa, Kiki, Cleophas, Maartje C P, Scribner, Curtis L, Skouras, Damaris B, Marchetti, Carlo, Dinarello, Charles A, Joosten, Leo A B
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!